Today at the Annual Meeting of the American Association for Cancer Research, IBEX Technologies Inc. (TSX:IBT), an innovator in the development of diagnostics and therapeutics for the management of cancer and arthritis, and the Ottawa Regional Cancer Center presented data on the possible cancer inhibiting effects of certain kallikreins.
